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Cystic fibrosis lung disease is characterized by chronic airway infections with the opportunistic pathogen Pseudomonas
aeruginosa and severe neutrophilic pulmonary inflammation. P. aeruginosa undergoes extensive genetic adaptation
to the cystic fibrosis (CF) lung environment, and adaptive mutations in the quorum sensing regulator gene lasR
commonly arise. We sought to define how mutations in lasR alter host-pathogen relationships. We demonstrate
that lasR mutants induce exaggerated host inflammatory responses in respiratory epithelial cells, with increased
accumulation of proinflammatory cytokines and neutrophil recruitment due to the loss of bacterial protease–
dependent cytokine degradation. In subacute pulmonary infections, lasR mutant–infected mice show greater neu-
trophilic inflammation and immunopathology compared with wild-type infections. Finally, we observed that CF
patients infected with lasR mutants have increased plasma interleukin-8 (IL-8), a marker of inflammation. These
findings suggest that bacterial adaptive changes may worsen pulmonary inflammation and directly contribute to






Progressive lung disease is the primary cause of symptoms and early
death in patients with the genetic disease cystic fibrosis (CF). In the CF
airways, chronic bacterial infections are associated with an exuberant
neutrophil-dominant inflammatory response that causes lung damage.
Most CF patients are chronically infected with the opportunistic path-
ogen Pseudomonas aeruginosa for decades. Because host defenses fail
to clear bacteria, the ongoing interplay between pathogen and host
drives inflammation and the immunopathology associated with CF
chronic P. aeruginosa infections (1, 2).
During its residence within the host, P. aeruginosa evolves and ge-
netically adapts to the CF lung environment (3–10). P. aeruginosa iso-
lates from chronic infections differ genotypically and phenotypically
from those isolated at early stages of infection or from the environment,
and commonly display adaptive changes such as conversion to mucoidy
or loss of motility. Strikingly, CF-adapted P. aeruginosa isolates have
reduced expression of acute virulence factors such as pilus, extracellu-
lar toxins, and enzymes that cause invasive disease (3, 7–10), suggest-
ing that bacterial factors required for acute virulence are not necessary
for chronic infections.
Quorum sensing is a bacterial communication system that allows
organisms to coordinate the expression of genes implicated in infection
pathogenesis and social microbial behavior in a cell density–dependent
manner (11). The P. aeruginosa transcriptional factor LasR is one ofthe major quorum sensing regulators and controls the expression of
several exoproducts and acute virulence factors (12).
lasR mutants arise from P. aeruginosa populations in both in vitro
laboratory conditions (13, 14) and in vivo during human infections
(4, 8, 15, 16). At least a third of chronically infected CF patients harbor
loss-of-function lasRmutants (8, 17, 18), and these patients are associated
with worse lung function (17). Given that lasR mutants are highly at-
tenuated in models of acute infections (10, 19, 20), this striking paradox
raises the possibility that CF-adapted P. aeruginosa variants contribute
to the progression of CF lung disease through mechanisms distinct
from those involved during acute infections. How the adaptive micro-
evolution of P. aeruginosa modulates host-pathogen relationships and
inflammatory responses remains incompletely understood.
Here, we defined the impact of P. aeruginosa lasR mutants on in-
flammatory responses in vitro, in vivo, and in CF patients. We observed
that lasR mutants induced an exaggerated neutrophil-dominant hyper-
inflammatory response, and dissected the mechanism for this pathogen-
host interplay. Our findings suggest a mechanism by which CF-adapted
P. aeruginosa lasR variants amplify the inflammation of CF lung disease,
thus potentially accelerating disease progression.RESULTS
Loss-of-function lasR mutation attenuates acute virulence in
a CF-adapted P. aeruginosa “late” isolate
Using a pair of P. aeruginosa clonally related longitudinal isolates (21),
Smith et al. previously examined the earliest (“early”) isolate recovered
from a CF patient at 6 months of age, and the late isolate from the
same patient at age 8 years (8). Using whole genome sequencing, they
demonstrated that the CF-adapted late isolate underwent adaptive ge-
netic evolution during chronic infection. Similar to many CF-adapted
P. aeruginosa isolates, the late isolate has several loss-of-function
mutations resulting in the loss of pilus-mediated twitching motility1 of 15
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nload(pilA), pyocyanin (phzS), and pyoverdine (pvdS) production com-
pared to the early isolate (fig. S1). Notably, the late isolate also carries a
loss-of-function nonsense mutation in the lasR gene [1–base pair (bp)
deletion at position 147], in contrast to a wild-type lasR gene sequence
in the early isolate (8).
lasR mutants induce an inflammatory cytokine response in
airway epithelial cells
To begin understanding the consequences of lasR mutations on host
responses, we first examined the airway inflammatory responses to the
early and late pair of isolates. In the CF lung, P. aeruginosa grows as
biofilm-like aggregates embedded within the mucus layer overlying the
airway epithelial surface (22), and the airway epithelium is critical in
producing proinflammatory cytokines in response to bacterial stimuli
to recruit neutrophils to sites of inflammation (23–26). We therefore
used a biofilm–airway epithelial cell (AEC) coculture model where
P. aeruginosa biofilm aggregates grew in a gel matrix (27) within syn-LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015thetic CF sputum medium, a defined culture medium that approximates
the nutrient composition of CF sputum (28). Human immortalized
AECs were cocultured with live biofilms across a permeable membrane
(depicted in Fig. 1A), and we measured the major proinflammatory
cytokines, interleukin-8 (IL-8) and IL-6, secreted in the AEC culture su-
pernatant (29, 30). Surprisingly, late isolate biofilms were more proin-
flammatory than were early isolate biofilms: after 24 hours in coculture
with P. aeruginosa biofilms, secreted IL-8 and IL-6 levels were respec-
tively 1.7-fold (P≤ 0.01) and 4.7-fold (P≤ 0.001) higher in AECs stim-
ulated with late compared to those stimulated with early isolate biofilms
(Fig. 1B). To examine the specific contribution of the lasRmutation to
this effect, we also tested the EDlasRmutant, an early isolate harboring
a genetically engineered lasR knockout mutation. AECs cocultured with
EDlasR biofilms also produced IL-8 levels equivalent to those in AECs
cocultured with late isolate biofilms and 1.8-fold higher (P ≤ 0.05) than
those in AECs cocultured with early isolate biofilms (Fig. 1B). Similarly,




















































































































































































Fig. 1. lasRmutants induce a proinflammatory cytokine response in several airway epithelial culture systems. (A) Schematic and photograph (top
view) of a biofilm-AEC coculture system with P. aeruginosa biofilm aggregates grown for 48 hours in synthetic cystic fibrosis sputum medium (SCFM) with
0.8% agar in a Transwell permeable support. (B) BEAS-2B cells cocultured with early, late, and EDlasR biofilm aggregates (or media control) for 18 hours.
(C and D) BEAS-2B cells stimulated with filtrates from early, late, or EDlasR isolates for 8 hours at the indicated volumes. (E) CFBE41o- (DF508/DF508) cells
stimulated with 30 ml of early, late, and EDlasR filtrates for 18 hours. (F) Ex vivo nasal explants stimulated with 60-ml filtrates or media control for 24 hours.
IL-6 and IL-8 levels in the AEC culture conditioned supernatants after coculture with biofilm aggregates or stimulation with bacterial filtrates were
measured by sandwich enzyme-linked immunosorbent assay (ELISA). Results in (B) to (E) are shown as mean ± SEM (n ≥ 3 independent biological
replicates, representative of ≥2 independent experiments). Statistical comparisons for (B) to (E) were done using a two-tailed t test (versus the early group).
Results in (F) are shown as median [±interquartile range (IQR)] of independent biopsies (n = 7 patients), and statistical comparison was done using the
Kruskal-Wallis test (versus control group). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. NS, not significant (P > 0.05).2 of 15










(P ≤ 0.05) higher compared to AECs stimulated with early isolate
biofilms.
Because both late and EDlasR isolates induced higher secreted cy-
tokine levels than the early isolate in the biofilm-AEC coculture system,
we hypothesized that the cytokine responses were dampened by LasR-
dependent extracellular bacterial products because LasR controls the
production of many secreted factors. To test this hypothesis, we stim-
ulated AECs with P. aeruginosa cell-free filtrates that contained diffus-
ible bacterial products, and again noted that lasR mutants (both late
and EDlasRmutants) elicited higher secreted IL-8 and IL-6 levels than
did the parental early isolate. As shown in Fig. 1C, the cytokine response
to late filtrates was dose-dependent, with IL-8 levels ~3- to 10-fold and
IL-6 levels ~6- to 120-fold higher than equivalent stimulation with early
filtrates. Results with the EDlasRmutant filtrates were similar to those of
the late isolate (Fig. 1D), indicating that the increased cytokine response
was predominantly attributable to lasR mutations. Control experiments
showed that all P. aeruginosa isolates grew to similar bacterial densities
in planktonic and biofilm cultures (fig. S2). P. aeruginosa cell-free fil-
trates and live biofilms also caused minimal cytotoxicity (fig. S3, A and
B) and loss of viability (fig. S3C) to AECs.
To validate our initial observations with AECs, we tested two ad-
ditional airway epithelial culture systems. We used CFBE41o- cells, which
are a CF AEC line homozygous for the DF508 mutation in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene (31) (Fig.
1E), and ex vivo primary human nasal tissues (Fig. 1F) that contain
morphologically intact primary upper respiratory tract epithelial cells,
as well as stromal structures and immune cells. Stimulation with fil-
trates from lasR mutants induced the highest IL-8 and IL-6 levels in
both systems.
Loss of LasR function causes an exaggerated
neutrophil-dominant hyperinflammatory response in vivo
The results from our in vitro experiments demonstrated that lasRmu-
tants caused a hyperinflammatory IL-8 and IL-6 cytokine response in
AEC. We therefore hypothesized that infection with lasR mutants will
increase pulmonary recruitment of neutrophils and an exaggerated in-
flammatory response in vivo compared with the early isolate, which
carries a wild-type lasR gene. To test this hypothesis, we infected C57BL/6
mice with P. aeruginosa embedded in agar beads to create a chronic
airway infection model (32, 33). P. aeruginosa embedded in agar beads
approximate the endoluminal bacterial aggregates observed in chronic
CF airway infections by impairing bacterial clearance and create a sub-
acute and nonlethal pulmonary infection. Despite identical bacterial
burden at both day 1 and day 4 post-infection (p.i.) (fig. S4A), mice
infected with the EDlasRmutant showed significantly greater neutrophil-
dominated pulmonary inflammation than did those infected with the
early isolate. At day 4 p.i., the bronchoalveolar lavage fluid (BALF) of
EDlasR-infected mice contained 9.5-fold (P ≤ 0.01) more leukocytes
(CD45+) and 25-fold (P ≤ 0.01) more neutrophils (CD45+ CD11b+
Ly6Ghi) compared to the BALF of early isolate–infected mice (Fig.
2A). Similarly, we observed 8-fold (P ≤ 0.001) more leukocytes and
14-fold (P ≤ 0.001) more neutrophils in the whole-lung homogenates
of EDlasR-infected mice compared to early isolate–infected mice (Fig.
2B). Overall, neutrophils accounted for a greater proportion of leuko-
cytes in EDlasR-infected compared to early isolate–infected mice (93%
versus 27% in the BALF, P ≤ 0.01; 53% versus 26% in the lung, P ≤
0.01) (Fig. 2, C and D). To further characterize the inflammatory cytokine
response in vivo, we measured the BALF and plasma cytokine levels atLaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015day 4 p.i. Both BALF levels of KC (keratinocyte-derived cytokine, a
murine functional homolog of the human neutrophil chemokine IL-8)
and IL-6 were significantly higher in the EDlasR-infected group, with
8-fold increase for KC (P < 0.001) and 10.5-fold increase for IL-6 (P <
0.01) compared to the early group (Fig. 3A), consistent with the vig-
orous neutrophil recruitment to the lung. Blood KC and IL-6 levels
also showed similar differences between the early isolate–infected
and EDlasR-infected groups (Fig. 3B).
Histology revealed peribronchial polymorphonuclear leukocyte
(PMN)–dominant inflammatory foci associated with agar-embedded
endoluminal P. aeruginosa beads. We also observed scattered areas of
PMN-dominant parenchymal inflammation (Fig. 3C). Lungs infected
with the EDlasR mutant, but not the early isolate, displayed rare areas
of airway necrosis and alveolar fibrin accumulation, suggesting more
pronounced localized tissue damage. We scored the airway and paren-
chymal inflammation in histological sections of the lung tissue, and only
the EDlasR–infected lungs showed inflammation significantly above the
control group (Fig. 3D). We also found higher total protein levels in the
BALF, a marker of lung tissue damage, in the EDlasR-infected mice
compared to the early isolate–infected ones (Fig. 3E). Together, these
results show that the loss of LasR function in P. aeruginosa increases
neutrophil recruitment and worsens lung immunopathology in vivo.
LasR-regulated proteases directly degrade secreted cytokines
Cytokine levels in the conditioned supernatants of AECs stimulated
with the early isolate were at times below those in control conditions
or nearly undetectable (Fig. 1, D and E), leading us to hypothesize that
secreted cytokines were degraded by LasR-controlled factors absent in
the late isolate and EDlasR mutant. To test this hypothesis, we first
measured cytokine mRNA expression and secreted cytokine levels simul-
taneously in AECs stimulated with early and late filtrates in a time-
course experiment, and observed that the differences in secreted
cytokines could not be attributed to the IL-8 and IL-6 mRNA re-
sponse (fig. S5). Furthermore, heat treatment of early filtrates restored
AEC cytokines to levels greater than those in the late filtrate treatment
group (Fig. 4A). These findings suggested that heat-labile bacterial
factors significantly dampened secreted cytokine levels, likely through
a post-secretion degradation process, and heat inactivation of the early
filtrates uncovered the cytokine response to other bacterial factors
present in those filtrates.
Because LasR regulates the expression of many extracellular fac-
tors, including heat-labile proteases, we next asked whether LasR-
controlled proteases directly degraded IL-8 and IL-6. Consistent with
our hypothesis, the late isolate and EDlasR mutant both had nearly
undetectable extracellular total protease and elastase activities com-
pared to the early isolate, and both activities in the early isolate were
heat-labile (Fig. 4, B and 4C). To confirm that LasR-regulated factors
directly degraded IL-6 and IL-8, we incubated recombinant human IL-6
(rhIL-6) and IL-8 (rhIL-8) proteins with P. aeruginosa filtrates that
contained secreted bacterial products. The early isolate filtrate degraded
both cytokines, and this proteolytic degradation activity was abrogated
by heat treatment (Fig. 4D). In contrast, both rhIL-6 and rhIL-8 pro-
tein levels remained intact when incubated with late or EDlasR filtrates
(Fig. 4D).
Because LasR-dependent regulation of proteases varies among dif-
ferent strains of P. aeruginosa (34), we then measured protease pro-
duction by the laboratory strain PAO1-V (35) and four different CF
clinical isolates carrying functional wild-type lasR alleles (36) and3 of 15










compared them to their respective genetically engineered lasR knock-
out mutants. As observed with the early isolate, all of the P. aeruginosa
isolates displayed extracellular total protease (Fig. 5A) and elastase ac-
tivities (Fig. 5C) that were abolished by lasR mutations. All wild-type
parental strains also induced significantly less IL-6 and IL-8 compared
with their isogenic lasR mutants (Fig. 5D). Because loss of protease
activity is commonly seen in CF-adapted P. aeruginosa isolates (37, 38),
we also examined pairs of clonally related longitudinal P. aeruginosa
isolates collected from three other CF patients (described in table S1).
The CF-adapted isolates L1, L2, and L3 produced less elastase (Fig. 5E)
and induced more IL-6 and IL-8 production in AECs compared to their
paired early isolates E1, E2, and E3, respectively (Fig. 5F). Together,
these results indicate that LasR-dependent proteolytic degradation of
cytokines occurs in multiple P. aeruginosa isolates, and this is a major
mechanism in the hyperinflammatory cytokine response associated
with protease-deficient isolates.LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015Bacterial proteases degrade cytokines more efficiently than
does neutrophil elastase
Previous studies have reported that neutrophil elastase (NE) can de-
grade IL-6 and IL-8 (39, 40). Because this enzyme is abundant in the
airways of CF patients (41), we compared the cytokine-degrading ac-
tivities of NE with those of P. aeruginosa proteases. At quantities titrated
to a specific elastase activity equivalent to purified human NE (2 mg/ml )
(fig. S6), filtrates from P. aeruginosa clinical isolates potently degraded
both rhIL-6 and rhIL-8, but NE did not (Fig. 5B). Extracellular bacterial
proteases thus likely contribute significantly to cytokine degradation.
LasB, a LasR-regulated elastase, is required for IL-8
and IL-6 degradation
LasR positively regulates the expression of several P. aeruginosa extra-
cellular proteases, including LasA, LasB, and AprA. To determine which
















































































































































Fig. 2. Loss of LasR function causes a neutrophil-dominant hyperinflammatory response in murine P. aeruginosa pulmonary infections.
(A) Number of leukocytes (CD45+) and neutrophils (CD45+ CD11b+ Ly6Ghi) in BALF. (B) Number of leukocytes (CD45+) and neutrophils (CD45+ CD11b+Ly6Ghi) in whole lung homogenates. (C) Representative flow cytometry scatter plots of neutrophils (CD45+ CD11b+ Ly6Ghi) in the BALF and whole-lung
homogenates. Insets show the proportion of CD11b+ Ly6Ghi cells of total live CD45+ cells. (D) Proportion of neutrophils (CD45+ CD11b+ Ly6Ghi) of all
leukocytes (CD45+) in BALF and whole lungs. Mice in the PBS (phosphate-buffered saline) control groups are inoculated with sterile PBS agar beads. All
results are from samples collected at day 4 p.i. Results in (A), (B), and (D) are shown as median (n ≥ 5 mice) of each group. Statistical comparison was done
using the Mann-Whitney test as indicated. **P ≤ 0.01; ***P ≤ 0.001.4 of 15










AECs with culture filtrates from the PAO1-V wild-type strain and its
isogenic aprA, lasA, and lasB mutants. The lasB mutation had the
same effect on cytokine degradation as did lasR mutations, whereas
deletion of aprA and lasA had no significant effect (Fig. 6A). To con-
firm the role of LasB, we deleted lasB in the early isolate and comple-
mented the late isolate with an inducible lasB gene, thus creating the
EDlasB and L+lasB strains, respectively. As shown in Fig. 6B, the EDlasB
isolate induced a proinflammatory cytokine response, whereas overex-
pression of lasB in the late isolate restored cytokine degradation.
Together, our results show that the LasB is necessary and sufficient
to degrade IL-6 and IL-8 in AEC cultures.
Loss of P. aeruginosa LasB activity stimulates
neutrophil recruitment
If the LasB-mediated cytokine degradation contributes to the hyperin-
flammatory responses of lasR mutants, we reasoned that the loss of
LasR and LasB function should be sufficient to increase neutrophil re-
cruitment. To test this hypothesis, we used a neutrophil transmigra-
tion assay to determine the functional consequences of AEC cytokineLaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015response on primary human neutrophil recruitment and chemotaxis
in vitro. We collected the conditioned supernatant from AECs stimulated
with early, late, EDlasR, and EDlasB filtrates and measured the effects
of these supernatants on neutrophil chemotaxis and transmigration.
As shown in Fig. 6C, conditioned supernatant from AECs stimu-
lated with late, EDlasR, and EDlasB filtrates induced 4.5-, 3.5-, and 6.8-
fold greater neutrophil transmigration, respectively, compared to
AECs stimulated with early filtrates (all P < 0.001). These results therefore
demonstrate that P. aeruginosa mutants lacking LasB function, through
either mutation of lasB or inactivation of its transcriptional regulator lasR,
induce greater neutrophil recruitment than do wild-type P. aeruginosa.
Chronic airway infection with P. aeruginosa lasR mutants is
associated with higher levels of plasma IL-8 in CF patients
On the basis of our in vitro and in vivo results, we predicted that chron-
ic lasR mutant infections would also be associated with a hyperinflam-
matory response in CF patients. In a prospective cohort of 17 adult CF
patients chronically infected with P. aeruginosa, we analyzed patients’
whole-sputum samples by FREQ-seq analysis (42) to determine the rel-A B
C


























































































Fig. 3. Greater pulmonary inflammation, systemic inflammation, and lung injury in EDlasR-infected mice. (A) Cytokine measurement in BALF. (B)
Cytokine measurement in plasma obtained from whole blood. (C) Representative hematoxylin and eosin (H&E)–stained lung sections visualized with a 4×
(scale bar, 500 mm) or a 20× (scale bar, 100 mm) objective. (D) Total inflammation score. (E) Total protein in BALF. All results are from samples collected at
day 4 p.i. Results in (A), (B), and (E) are shown as mean (n ≥ 4 mice) of each group, and results in (D) are shown as median (n ≥ 3 mice). Statistical
comparison was done by two-tailed unpaired Student’s t test for (A), (B), and (E) and by Mann-Whitney test for (D) as indicated. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.5 of 15










ative frequency of lasR mutant alleles, defined by the identification of
nonsynonymous mutations within the lasR coding sequence. As shown in
Fig. 7A and fig. S7A, some patients were colonized withmixed P. aeruginosa
populations with both wild-type and mutant lasR alleles. We defined pa-
tients’ lasR status as lasRmut if their sputum P. aeruginosa populations con-
tained >50% lasRmutant alleles and as lasRwt if they contained <50% lasR
mutant alleles. On the basis of the frequency of lasRmutant alleles in their
sputum samples, 8 of 17 patients were considered lasRmut (Fig. 7A), and
the lasRmut and lasRwt groups were similar in age (fig. S7B) and gender
(female, 50% versus 55% in the lasRmut and lasRwt groups, respectively).
We concurrently measured the subjects’ plasma levels of IL-8, a systemic
marker of inflammation in CF lung disease (43, 44). The lasRmut group
had higher IL-8 levels compared to the lasRwt group during a stable clin-
ical state [median (IQR), 6.2 (4.7 to 18.7) versus 3.4 (2.7 to 5.2), P≤ 0.03]
(Fig. 7B), and results remained similar even when the patients’ lasRmut
status was defined as >20 or >90% lasR mutant alleles instead of
>50%. Notably, the lasRmut group was still associated with higher IL-8LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015levels when patients were assessed longitudinally [median (IQR), 6.4
(5.0 to 16.0) versus 3.9 (3.2 to 7.1), P ≤ 0.005] (fig. S7C), with a positive
correlation between lasRmutant allele frequency and IL-8 levels (Spear-
man r = 0.33; 95% CI, 0.03 to 0.58; P ≤ 0.05) (Fig. 7C). These results
thus show a significant association between airway infections with
lasR mutants and a marker of inflammation in CF patients.DISCUSSION
During the transition from initial to chronic infection, P. aeruginosa
adapts to the CF lung environment and incurs genotypic and pheno-
typic changes resulting in reduced expression of invasion and toxicity
factors (3, 4, 6–10, 45–49). Although such CF-adapted P. aeruginosa
mutants should be attenuated in virulence and induce less pathology,
in CF patients they are in fact associated with later stages of lung dis-





Heat treatment: – – – – – + – – – – – + – – – – – +
Early Late E∆lasR
0 0.5 3 12 24 24 0 0.5 3 12 24 24 0 0.5 3 12 24 24
rhIL-6
























































Fig. 4. LasR-regulated proteases directly degrade cytokines. (A) BEAS-2B cells stimulated with heat-treated early or late filtrates for 8 hours at the
indicated volumes. IL-6 and IL-8 levels in the AEC conditioned supernatant after stimulation were measured by sandwich ELISA. (B) Total secreted protease
activity in filtrates (+/− heat treatment) on skim milk agar plates. (C) Specific elastolytic activity in filtrates (+/− heat treatment) using the elastin Congo red
assay. (D) rhIL-6 or rhIL-8 (10 mg/ml) incubated with filtrates (+/− heat treatment) starting at time 0. The rhIL-6 or rhIL-8 levels were measured by
SDS–polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blot. Bar graphs indicate the relative amounts of protein measured by
band densitometry analysis relative to T = 0. Results in (A), (C), and (D) are shown as mean (±SEM) and are representative of at least three
independent experiments. Statistical comparisons were done using a t test compared with the early group for (A) and (C), and with T = 0 in the same
condition for (D). *P < 0.05; **P < 0.01; ***P < 0.001.6 of 15










Fig. 5. P. aeruginosa CF clinical isolates degrade cytokines, and protease-deficient isolates induce greater IL-8 and IL-6 response in AEC. (A) Total
secreted protease activity in filtrates from the laboratory strain PAO1-V, clinical isolates (CF1 to CF4), and their isogenic DlasRmutants assessed on skimmilk
agar plates. (B) rhIL-6 or rhIL-8 (10 mg/ml) incubated with filtrates or purified human NE (2 or 10 mg/ml) for 3 hours (rhIL-6) or 24 hours (rhIL-8). CF1 to CF4
filtrates were dosed at equivalent elastase activity as NE (2 mg/ml) (as demonstrated in fig. S6). (C) Specific elastase activity in filtrates using the elastin Congo
red assay. (D) BEAS-2B cells stimulated with 60-ml filtrates or media control for 24 hours. (E) Specific elastase activity in filtrates using the elastin Congo red
assay. E1-L1, E2-L2, and E3-L3 are clonally related longitudinal P. aeruginosa isolates from three CF patients (as outlined in table S1). (F) BEAS-2B cells stimu-
latedwith 60-ml filtrates ormedia control for 24 hours. For (D) and (F), IL-6 and IL-8 levels in the AEC-conditioned supernatant after stimulationweremeasured
by sandwich ELISA. Results in (C) to (F) are shown as mean (±SEM) of n = 3 independent biological replicates and are representative of n ≥ 2 independent
experiments. Statistical comparisons were done using a two-tailed t test as indicated. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015 7 of 15




























































































Fig. 6. Loss of LasR-regulated LasB abrogates IL-6 and IL-8 degradation and induces more neutrophil recruitment in vitro. (A) BEAS-2B cells stimu-
lated with 60-ml filtrates or media control for 8 hours from PAO1-V (wild-type), and its derived DaprA, DlasA, and DlasBmutants. (B) BEAS-2B cells stimulated
with 60-ml filtrates or media control for 8 hours from early, EDlasB, late, and L+lasB (complemented with lasB) isolates. (C) Human neutrophil transmigration
assay with conditionedmedium from BEAS-2B cells stimulated with 60-ml filtrates or media control for 24 hours. For (A) and (B), IL-6 and IL-8 levels in the AEC
conditioned supernatants after stimulationweremeasured by sandwich ELISA. Results are shown asmean (±SEM) of n = 3 independent biological replicates
and are representative of at least n≥ 3 independent experiments. Statistical comparisonsweredoneusing a two-tailed t test as indicated. *P≤ 0.05; **P≤ 0.01;
***P ≤ 0.001.LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015 8 of 15










explore this paradox, we focused on lasR mutants. Our study showed
that lasR mutants induce greater inflammation in vitro and in vivo
despite reduced expression of acute virulence factors. We demonstrated
that LasB, a LasR-controlled protease, degraded cytokines, and loss of
LasB-dependent proteolysis was sufficient to cause an exaggerated in-
flammatory response in vitro under biologically relevant conditions.
Notably, the loss of LasR function also induced an exaggerated cyto-
kine response associated with increased pulmonary neutrophilic inflam-
mation and airway tissue damage in murine airway infections. These
findings thus support a model wherein adaptive lasR mutants directly
contribute to exaggerated cycles of infection and inflammation, lead-
ing to progression of CF lung disease. Consistent with this model, CF
patients predominantly infected with lasR mutants had higher plasma
IL-8 levels than those predominantly infected with wild-type P. aeruginosa,
whereby circulating IL-8 levels are markers of inflammation elevated
in CF lung disease (43, 44). Whether lasRmutants cause worsening of
lung function over time in CF patients still needs to be addressed in a
longitudinal study.
Airway inflammation in CF lung disease is dominated by neutro-
phils and directly contributes to pulmonary dysfunction and tissue
damage (2, 50–52). P. aeruginosa typically grows as biofilm aggregates
within the viscous mucus layer overlying the airway epithelial surface
and is not invasive in CF chronic infections (22, 53). AECs thus in-
teract with extracellular bacterial products to produce proinflamma-
tory mediators critical for recruitment of neutrophils to the sites of
inflammation. These interactions are modeled in our experimental
systems, and we observed the hyperinflammatory effects associated
with lasR mutants across several cell culture systems, including CF
and non-CF AECs, immortalized as well as primary human cells,
using both genetically engineered and naturally occurring lasR mu-
tants. We recognize that our murine infection model overlooks the
contribution of host CFTR mutations (which cause CF disease) on
host defenses and immunity and is not a model of CF lung disease
per se. However, it nonetheless provides a well-established in vivo sys-
tem to dissect the host-pathogen interactions during chronic infection
and their effects on pulmonary immunopathology.LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015At first glance, our findings contrast with previous studies report-
ing on the proinflammatory effects of LasR-regulated factors. For
example, the LasR-dependent quorum sensing signal 3-oxo-C12HSL (3-
oxo-dodecanoyl-homoserine lactone) can directly interact with host
cells via multiple different mechanisms (54), such as activating NF-kB
(nuclear factor k-light-chain enhancer of activated B cells), MAPK
(mitogen-activated protein kinase), and Ca2+-dependent signaling path-
ways, leading to induction of proinflammatory cytokine responses
(55–59). Azghani et al. (60, 61) also reported that LasB can activate
MAPK and NF-kB inflammatory signaling pathways in host cells. In
contrast to ours, these studies focus on host intracellular signaling re-
sponses and mRNA and intracellular cytokine levels and do not cap-
ture the contribution of post-secretion cytokine degradation, the major
mechanism investigated in our studies. Our results with heat-inactivated
filtrates or protease-deficient mutants are in fact consistent with the
notion that additional LasR-regulated factors can induce IL-8 and
IL-6 production.
However, the resulting secreted cytokine levels are only elevated in
the absence of bacterial protease activity. Because protease-mediated
cytokine degradation occurs after cytokines are secreted, this process
can prevail over more “upstream” bacteria-host interactions that mod-
ulate AEC cytokine expression. LasR controls the expression of extra-
cellular proteases in many P. aeruginosa strains (62, 63), including the
clinical and laboratory strains tested in this study, and LasB can be
detected at levels exceeding 100 mg/mg in the sputum of CF patients
(64). In protease-deficient P. aeruginosa clinical strains, the loss of pro-
tease activity is primarily caused by the loss of LasB elastase produc-
tion (65, 66).
Although the P. aeruginosa elastase LasB is established as an acute
virulence factor that degrades host matrix proteins and causes tissue
damage (67–69), its dual immunomodulatory role is likely under-
recognized because our results show that it degrades cytokines more
potently than does human NE. In settings where immune responses
fail to clear bacteria, such as in the CF airways, the loss of bacterial
elastase activity paradoxically amplifies pulmonary neutrophilia owing
to reduced cytokine degradation.Fig. 7. Colonization with lasR mutant P. aeruginosa is associated with higher plasma IL-8 in CF patients. (A) Frequency of lasR mutant alleles
measured by FREQ-seq in the 17 CF patients, with each dot representing one patient’s sputum sample collected during a clinically stable state. The
patients’ lasR status is defined as lasRwt or lasRmut, as shown. (B) Plasma IL-8 levels measured in clinically stable CF patients according to their lasRwt
or lasRmut status. Results are shown as median (lasRwt group, n = 9 patients; lasRmut group, n = 8 patients). Statistical comparison was done using the
Mann-Whitney test compared with the lasRwt group. *P ≤ 0.05. (C) Linear correlation between lasR mutant allele frequency and plasma IL-8 levels in
longitudinal sampling of CF patients (n = 17). Spearman correlation r = 0.33; 95% confidence interval (CI), 0.03 to 0.58. P ≤ 0.05.9 of 15










LasR-regulated proteases could modulate host inflammatory re-
sponses through multiple pathways. For example, P. aeruginosa pro-
teases are capable of degrading in vitro cytokines such as RANTES
(regulated on activation, normal T cell expressed and secreted),
MCP-1 (monocyte chemotactic protein 1), and ENA-78 (epithelial-
derived neutrophil activating peptide 78, or CXCL5) (70–72). We focused
on IL-8 and IL-6 because AECs secrete them abundantly in response to
P. aeruginosa to recruit and activate neutrophils (73–76). Sputum IL-8
levels are higher in CF patients infected with P. aeruginosa (77)
and correlate with decreased lung function (41, 78, 79). LasB can degrade
surfactant proteins A and D, leading to resistance to phagocytosis
(80–82), and AprA can degrade flagellin monomers, thus dampening
TLR5 (Toll-like receptor 5)–mediated responses (83). These observa-
tions add to the proposed notion that P. aeruginosa proteases disrupt
host inflammatory responses, and their loss in CF-adapted P. aeruginosa
isolates could promote further inflammation.
In many P. aeruginosa strains, the quorum sensing regulator LasR
controls the expression of a number of acute virulence determinants,
including proteases, pyocyanin, and other exoproducts (84, 85). Ac-
cordingly, lasR mutants are attenuated in several models of acute vir-
ulence such as in invertebrate host models (14, 86) and rodent acute
pneumonia (20, 85, 87). That the loss of LasR-regulated acute viru-
lence factors does not prevent P. aeruginosa chronic infections sup-
ports the notion that CF-adapted mutants contribute to the pathogenesis
of chronic infection through pathways and host-pathogen relationships
different from those involved in acute infections (6).
A convergent adaptive evolution is consistently observed across
different P. aeruginosa populations in spite of the vast genetic hetero-
geneity within and between CF patients (4, 8, 49). Significantly, loss-of-
function lasR mutants commonly arise during chronic P. aeruginosa
infections to become a dominant variant or occur as part of a mixed
P. aeruginosa population in the CF lung (8, 15, 17, 36). In a retrospec-
tive study of 30 CF patients, lasR mutant isolates were identified in
63% of patients (8). More recently, lasR mutant P. aeruginosa isolates
were isolated in 31% of CF patients, and those patients infected with
lasR mutants were associated with worse age-specific lung function
(17), underscoring the clinical relevance of our study. lasR mutants
can also emerge during the course of non-CF infections, such as in
populations of P. aeruginosa colonizing intubated patients on mechan-
ical ventilation (88). Furthermore, in a large prospective study of chil-
dren with CF, the presence of protease-deficient P. aeruginosa isolates
was among the best bacterial phenotypic predictors of chronic infec-
tion (37). Because many of the protease-deficient CF isolates are lasR
mutants (36), it follows that the loss of LasR-controlled quorum sensing
may also be a predictor of more severe chronic infections. Whether this
bacterial adaptation is a marker of more severe CF lung disease or
contributes to its progression was not addressed by these observational
clinical studies.
Loss-of-function lasR mutations emerge under certain laboratory
growth conditions and often coexist in mixed P. aeruginosa popula-
tions, as noted in our study and others (4, 13, 15–17). lasR mutants
may have a fitness advantage, such as growth on nitrate and aromatic
amino acid sources (36, 89), higher resistance to alkaline stress (90),
and ability to act as social cheaters in mixed P. aeruginosa populations
(13, 16, 91, 92). Increased b-lactamase activity may also contribute to
their selection under b-lactam antibiotic treatment (36). Despite these
observations, it remains unknown why lasRmutants emerge so readily
in the CF lung.LaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015Our results also raise some concerns regarding the proposed devel-
opment of inhibitors targeting LasR quorum sensing (93) or bacterial
proteases (94) as novel antimicrobial agents against P. aeruginosa. In
chronic CF infections, such agents could induce greater host inflam-
mation and thus cause more harm. Understanding how bacterial
adaptation during specific chronic infections modulates host re-
sponses and contributes to lung inflammation is critical in developing
antimicrobial therapies tailored to the different types and stages of in-
fection.MATERIALS AND METHODS
Bacterial strains, plasmids, and construction of mutants
The bacterial isolates and plasmids used in this study are listed in tables
S2 and S3, respectively. The early (AMT0023-30) and late (AMT0023-34)
isolates, recovered from the same CF patient at 6 months and 8 years
of age, respectively, are clonally related and previously described (8).
The isolates CF1, CF2, CF3, and CF4 were isolated from four dif-
ferent CF patients (36), and their isogenic lasR mutants were geneti-
cally engineered (36). The longitudinal isolates E1, E2, and E3 and
their respective CF-adapted isolates L1, L2, and L3 were clonally related
and were recovered from three different CF patients. The construction
of the DlasB and DlasR mutants and the inducible lasB+ expression
construct is described in detail in the Supplementary Methods.
Bacterial planktonic and biofilm growth conditions
Bacteria were grown at 37°C in SCFM, a defined culture medium that
approximates the nutrient composition of CF sputum (28), unless
otherwise specified. Planktonic cultures were grown in liquid medium
with shaking at 250 rpm. Biofilms were grown as aggregates em-
bedded in agar as described previously (27), with modifications. Brief-
ly, biofilm cultures were inoculated with overnight planktonic cells
diluted in 50% SCFM, 20 mMNaNO3, and 0.8% melted agar to a final
concentration of 5000 cell/ml. Biofilm cultures were grown in 12-mm
Transwell permeable supports (Corning, 0.4-mm polyester membrane)
statically at 37°C for 48 hours. Antibiotics used for selection were gentam-
icin and tetracycline (50 and 80 mg/ml, respectively, for P. aeruginosa;
10 and 10 mg/ml, respectively, for Escherichia coli).
P. aeruginosa filtrate preparation
Planktonic bacterial cultures were grown in SCFM for 24 hours and
then centrifuged at 7200g for 10 min at room temperature. The super-
natants were filtered with low–protein binding 0.22-mm cellulose
acetate filters (Corning), and aliquots of sterile filtrates were stored
at −20°C, with no more than two freeze-thaws before use. Where in-
dicated, the filtrates were heat-treated for 10 min at 95°C to inactivate
proteases.
AEC cultures and stimulation with P. aeruginosa filtrates
Immortalized wild-type human bronchial epithelial BEAS-2B cells
were routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Wisent) containing D-glucose (4.5 g/liter) and supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Wisent), penicillin (100 U/ml),
and streptomycin (100 mg/ml) at 37°C with 5% CO2. For stimulation,
2 × 105 cells were seeded in tissue culture–treated 12-well polystyrene
plates (Corning Costar) and grown to confluence before the cells were
incubated in starvation medium (DMEM supplemented with 0.5%10 of 15










heat-inactivated FBS and antibiotics) for 16 hours; the cells were then
stimulated with 60 ml (or otherwise indicated) of sterile P. aeruginosa
filtrates or SCFM control medium in 1 ml of fresh starvation medium
and incubated at 37°C with 5% CO2 for the indicated time.
Immortalized CFBE41o- cells (31) were routinely cultured in Eagle’s
minimum essential medium (EMEM) containing D-glucose (1 g/liter)
and supplemented with 10% heat-inactivated FBS (Wisent), penicillin
(100 U/ml), and streptomycin (100 mg/ml) at 37°C with 5% CO2. For
stimulation, 2 × 105 cells were seeded in tissue culture–treated 12-well
polystyrene plates (Corning Costar) coated with human fibronectin
(10 mg/ml; VWR), bovine collagen I (29 mg/ml; BD Biosciences), and
bovine serum albumin (BSA; 100 mg/ml) in LHC basal medium
(Invitrogen) and grown to confluence. Before stimulation, the cells were
incubated in starvation medium (EMEM supplemented with 0.5% heat-
inactivated FBS and antibiotics) for 16 hours, then stimulated with 30 ml
of sterile P. aeruginosa filtrates or SCFM control medium in 1 ml of fresh
starvation medium, and incubated at 37°C with 5% CO2 for 18 hours.
For all experiments, the conditioned AEC supernatants were collected
after stimulation and stored at −20°C until further analyses.
Biofilm-AEC coculture system
Biofilm aggregates were grown for 48 hours as described above. Biofilm-
containing Transwells were then inserted into tissue culture wells
containing a confluent monolayer of BEAS-2B cells immersed in 1 ml
of starvation medium for co-incubation at 37°C with 5% CO2 for the
indicated time. For all experiments, the conditioned AEC culture su-
pernatants were collected after stimulation and stored at −20°C until
further analyses.
Ex vivo human nasal explant stimulation with
P. aeruginosa filtrates
Nasal explant specimens were obtained from human subjects 18 years
or older and diagnosed with chronic rhinosinusitis as previously de-
scribed (95). All subjects participated voluntarily with signed written
informed consent, as approved by the Institutional Review Board of
the Centre Hospitalier de l’Université de Montréal (CHUM). Surgical
specimens were washed in PBS and cut into pieces [mean weight, 6.9 ±
0.64 (SEM) mg]. Each tissue piece was cultured in a 3:1 mixture of
DMEM (Invitrogen) and Hanks’ buffer solution (Invitrogen) supple-
mented with penicillin (100 U/ml) and streptomycin (100 mg/ml) at
37°C with 5% CO2 for 72 hours, with replacement every 24 hours.
After 72 hours, the samples were stimulated for 24 hours with 60 ml
of P. aeruginosa filtrates or media control. The conditioned tissue su-
pernatant was collected after stimulation and stored at −20°C until
further analyses.
Cytokine measurements in conditioned AEC supernatants
Conditioned supernatants of AEC cultures or nasal explants were cen-
trifuged at 13,000g to pellet cell debris, diluted (1:10 to 1:100 as re-
quired), and used for cytokine quantification by ELISA. The levels
of IL-6 and IL-8 were quantified by ELISA (BD OptEIA Human
IL-6 and IL-8 ELISA kits, BD Biosciences) according to the manufac-
turer’s instructions. All measurements were done with at least three
independent biological replicates.
Chronic murine P. aeruginosa pulmonary infection
The pulmonary murine infection with agar-embedded P. aeruginosa
was performed as previously done (32). Briefly, planktonic bacterialLaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015cultures were grown to an OD600 (optical density at 600 nm) of 0.5 in
LB broth at 37°C with shaking at 250 rpm. Bacterial cells were pelleted
by centrifugation, resuspended in sterile PBS, and mixed 1:1 (v/v) with
a solution 2% LB and 3% molten agar. Agar-embedded P. aeruginosa
beads were generated with continuously stirring heavy mineral oil
(Fisher Scientific) as previously described (32), and the bacterial den-
sity was determined by standard dilution methods after homogenization
of beads. Sterile PBS LB agar beads were used in control experiments.
Specific pathogen–free, male C57BL/6 mice (6 to 9 weeks old) were
purchased from Charles River Laboratories. Anesthetized mice were
infected with 50 ml (~5 × 105 colony-forming units per mouse) of the
agar bead suspension using a noninvasive intratracheal inoculation
method as previously done (32). Mice were humanely sacrificed at de-
signated time points. Whole blood was collected by cardiac puncture,
and lungs were perfused with PBS to reduce blood leukocytes. Broncho-
alveolar lavage was performed by injecting and aspirating 4 × 500 ml of
sterile ice-cold PBS through an intratracheal catheter. After the BAL, the
lungs were removed and placed in sterile RPMI 1640 medium (Wisent)
containing protease inhibitors. For bacterial counts, whole lungs were
homogenized and serially diluted for viable bacteria plate counts.
All animal experiments were carried out in accordance with the Ca-
nadian Council on Animals Care and with approval from the Animal
Care Committee of the Research Institute of the McGill University
Health Centre.
BALF, lung homogenates, and plasma sample preparation
and analysis
The BALF was centrifuged to pellet cells, and aliquots of the super-
natant were frozen at −80°C until analysis. BALF total protein was mea-
sured using a bicinchoninic acid protein assay kit (Pierce). For lung
homogenates, perfused lungs were minced, digested with collagenase
(150 U/ml; Sigma-Aldrich), and filtered through a 100-mm pore size cell
strainer (BD). Red blood cells were removed by hypotonic lysis. The
remaining cells were pelleted, resuspended in 1 ml of sterile RPMI
1640, and quantified using an automated cell counter (Z1 cell counter,
Beckmann-Coulter). Murine plasma was collected from whole blood
mixed with 0.5 M EDTA, and aliquots were frozen at −80°C until anal-
ysis. Cytokines were quantified in all samples by ELISA (Mouse IL-6
and KC/CXCL8 DuoSet ELISA kits, R&D Systems).
Flow cytometry of BALF and lung homogenates
Cells (2 × 106) from lung single-cell suspensions or cells from 400 ml of
BALF were stained with Fixable Viability Dye eFluor780 (Affymetrix
eBioscience) and then blockedwith anti-murineCD16/CD32 (Affymetrix
eBioscience). Cells were then surface-stained with eFluor610-conjugated
anti-murine CD45 (30-F11, Affymetrix eBioscience), eFluor710-conjugated
anti-murineLy6G(1A8,AffymetrixeBioscience), andV500-conjugated anti-
murine CD11b (M1/70, BD). Finally, cells were fixed (Cytofix, BD) and
analyzed using LSR II flow cytometer (BD Biosciences) and FlowJo
10.0.7 software (Tree Star).
Lung histopathology
Murine lungs were inflated and fixed overnight with 10% buffered for-
malin phosphate (Fisher Scientific). Paraffin-embedded tissues were
sectioned into three 5-mm slices that were 50 to 500 mm apart. H&E-
stained sections were evaluated by a veterinary pathologist for inflam-
mation and pathology in a blinded manner. Images were acquired
using an Olympus BX51 microscope fitted with an Olympus DP7011 of 15










charge-coupled device camera. To assess the lung inflammation, a
semiquantitative score was used (see the Supplementary Methods), and
the average score of two sections was reported.
Cytokine degradation assay by immunoblotting
Lyophilized rhIL-6 or rhIL-8 (PeproTech) at 10 mg/ml final concen-
tration was incubated with P. aeruginosa filtrates [3% (v/v) final con-
centration] at 37°C. At specified times, 10-ml aliquots were mixed 1:1
(v/v) in tricine buffer [200 mM tris-HCl, 40% glycerol, 2% SDS, 0.04%
Coomasie blue G-250, 2% b-mercaptoethanol (pH 6.8)] and heated to
95°C for 5 min. Samples were then separated by SDS-PAGE with
16.5% tris-tricine gels. After transfer of gels onto nitrocellulose paper,
the blots were blocked with 2% BSA and then immunoblotted with poly-
clonal human IL-6 or IL-8 antibodies (R&D Systems) diluted in PBS
(with 0.1% BSA, 0.05% Tween 20). The signal was detected using don-
key a-goat secondary antibody conjugated to IRDye 800 infrared fluoro-
phore (Li-Cor Biosciences) in PBS with 0.05% Tween 20. Images of the
fluorescently labeled protein bands were captured with the Odyssey im-
aging system (Li-Cor Biosciences) and analyzed using ImageJ software
[1.47v, National Institutes of Health (NIH)]. The protein band density
was quantified and normalized to the T = 0 control on the same blot.
Skim milk agar protease activity assay
The total protease activity of the P. aeruginosa filtrates was assessed
using 1.5% agar plates containing 1.5% skim milk as previously de-
scribed (96). Briefly, P. aeruginosa filtrates were spotted onto sterile
6-mm paper discs placed on the agar surface, and the plates were in-
cubated for 24 hours at 37°C.
Elastase activity assay
Elastase activity in the P. aeruginosa filtrates was measured using the
elastin Congo red elastase assay as previously described with minor
modifications (97). Filtrates were incubated with ECR solution [elastin
Congo red (5 mg/ml; Sigma), 100 mM tris-Cl, 1 mM CaCl2 (pH 7.5)]
at 37°C for 24 hours with shaking at 250 rpm. Samples were then cen-
trifuged at 2200g for 10 min, and absorbance at 490 nm was measured
in the supernatant using a microplate reader (Bio-Rad, model 680).
All measurements were done with at least three independent biolog-
ical replicates.
In vitro PMN transmigration assay
PMNs were isolated from human blood (98), and samples contained
>99% neutrophils. Neutrophil transmigration assays were performed
as previously described using a modified Boyden chamber (99). Brief-
ly, 5 × 105 PMNs were added to the upper compartment of Transwell
inserts with 5-mm pore size permeable polycarbonate membrane
(Corning). Conditioned supernatants of stimulated AECs were added
to the Transwell lower compartment and incubated for 3 hours at 37°C
with 5% CO2. Cells from both upper and lower compartments were
collected and counted using a cell counter (Z1 Coulter, Beckman). The
percent neutrophil transmigration was defined as the percentage of
neutrophils in the basolateral compartment compared to the total
number of neutrophils in both compartments.
Clinical data and cytokine measurements in CF patients
CF patients from the Adult Cystic Fibrosis Clinic at the Montreal
Chest Institute (Montreal, Canada) were enrolled prospectively. Clin-
ical data, plasma sample collection, and cytokine measurements wereLaFayette et al. Sci. Adv. 2015;1:e1500199 31 July 2015previously described (100). Spontaneously expectorated sputum sam-
ples were collected and stored at −80°C until lasR FREQ-seq analysis.
All clinical data and samples were obtained either (i) at baseline during
a period of stable disease, defined by the absence of any pulmonary
exacerbations requiring antibiotic therapy in the preceding month, or
(ii) longitudinally over a period of 18 months during both stable and
exacerbation clinical states. Informed written consent was obtained
from all subjects, and the study was approved by the Institutional Re-
view Board of the McGill University Health Centre.
FREQ-seq analysis of lasR alleles in CF sputum
Genomic bacterial DNA was extracted from whole sputum using the
PowerSoil DNA Isolation Kit (Mo Bio Laboratories). The lasR gene
was amplified by polymerase chain reaction (PCR) with lasR-specific
primers lasR-F and lasR-R (see table S4 for primer sequences). PCR
products were purified using the QIAquick PCR purification kit (Qiagen).
Standard Illumina Nextera libraries were constructed using individual
PCR products according to the manufacturer’s guidelines (Illumina
Inc.). Paired-end libraries for each sample were sequenced with an
Illumina MiSeq to generate 150-bp reads for an average of at least
20,000 reads per base per sample. Sample sequences were aligned against
the lasR PAO1 reference sequence (www.pseudomonas.com) using
the BWA-MEM algorithm (101). All lasR polymorphisms identified
were present at a frequency of >5% in at least 10,000 reads of that given
sample. Nonsynonymous mutations within the lasR coding sequence
were considered mutant lasR alleles, and patients were considered
to be in the lasRmut group if the lasR mutant allele frequency was
>50% in that sample.
Statistical analyses
All results are expressed as mean ± SEM or median ± IQR as indi-
cated. Statistical analyses were done using Prism 5 software (GraphPad).
Comparisons were performed using an unpaired two-tailed Student’s t
test or the Mann-Whitney nonparametric test as indicated. Compar-
isons between three or more groups were performed using one-way
analysis of variance with Bonferroni’s test or Kruskal-Wallis nonparam-
etric test as indicated. A P value of ≤0.05 was considered to be statis-
tically significant. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
Accession numbers
Accession numbers for genes and proteins mentioned in the text (Na-
tional Center for Biotechnology Information Entrez gene ID number)
are as follows: P. aeruginosa pilA (878423), phzS (881836), pvdS (882839),
lasR (881789), aprA (881248), lasA (878260), and lasB (880368).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/6/e1500199/DC1
Materials and Methods
Fig. S1. The late isolate is impaired in the production of acute virulence factors compared to
the early isolate.
Fig. S2. The early, late, and EDlasR isolates grow to similar bacterial density in planktonic and
biofilm cultures.
Fig. S3. P. aeruginosa cell-free filtrates and biofilms do not cause significant cytotoxicity to AEC
cultures.
Fig. S4. The pulmonary bacterial loads are similar in early and EDlasR isolate–infected mice.
Fig. S5. Relative expression of IL-6 and IL-8 mRNAs in BEAS-2B cells treated with early and late
filtrates.
Fig. S6. Elastase activity of filtrates used to degrade rhIL-8 and rhIL-6.12 of 15
R E S EARCH ART I C L EFig. S7. Colonization with lasR mutant P. aeruginosa is associated with higher plasma IL-8 in CF
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Table S1. Clonally related E and L isolate pairs from CF patients.
Table S2. P. aeruginosa isolates and strains.
Table S3. Plasmids.
Table S4. Primers.
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